Pacific Biosciences of California, Inc. (NASDAQ:PACB) is listed among the 12 Best Genomics Stocks to Invest In. Barclays analyst raises price target for PACB to $2 and maintains Equal Weight rating, citing favorable market backdrop. Last quarter’s revenue fell short due to lower than expected Vega sales in Europe.

PACB anticipates 10% sequential revenue growth in Q4, driven by higher Revio placements. Reduced sales projections for 2025 to $155-160 million. Company develops innovative DNA sequencing technology for researchers. While PACB shows investment potential, some AI stocks offer greater upside with less risk.

Read more at Yahoo Finance: Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB)